Q-omics provides the consensus-scored CT83 profile across patient tissues and cancer cell-line models. CT83 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CT83 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, CT83 RNA expression shows 7,435 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, STAD, and ESCA as cancer lineages where CT83 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CT83 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CT83 survival associations across molecular data types. CT83 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CT83 RNA expression–survival associations across cancer types. High CT83 expression shows unfavorable associations in KICH, KIRP, LIHC, DLBC, ACC and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CT83 RNA expression.
This table summarizes CT83 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in STAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CT83. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CT83 shows higher tumor expression in STAD, LUAD, LUSC, ESCA, BRCA and UCEC. The STAD box plot shows higher CT83 RNA expression in tumor versus normal tissue (log2 FC = +2.826, t-test p < 0.001).
This table shows molecular features associated with CT83 in patient tissues and cancer cell lines. In patient samples, CT83 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CT83 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
